Tailored treatment for hepatitis C.
Considering the high number of global cases of hepatitis C virus (HCV) infection (around 175 million), effective, individualized, tailored treatment approaches are imperative. In this respect, defining patients according to their initial response profiles was shown to have great impact on choosing the optimal treatment duration. The application of new more sensitive HCV RNA tests may further help to improve treatment individualization. In spite of the many relevant studies conducted in the past and at present, however, this problem is far from being resolved. Generally, it can be said that the presence of a rapid virologic response is a significant predictor of favorable outcome and permits an abbreviated treatment period. In contrast, patients who have a slow response have a high risk for relapse but seem to profit from extending treatment duration. This viral kinetically driven approach to tailor treatment is generally applicable to all genotypes.
Berg
Thomas
T
Medical Department Hepatology and Gastroenterology, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany. thomas.berg@charite.de <thomas.berg@charite.de>
D000998:Antiviral Agents / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D012367:RNA, Viral / Q000187:drug effects; D016896:Treatment Outcome
D000998:Antiviral Agents; D012367:RNA, Viral